In transplant, GLP-1 RA is recommended by most guidelines as a second-line alternative to SGLT2i after metformin in managing T2DM, especially with CVD, CV risk factors, or CKD. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.